148 related articles for article (PubMed ID: 37914862)
1. Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events.
Montes-Grajales D; Garcia-Serna R; Mestres J
Sci Rep; 2023 Nov; 13(1):18817. PubMed ID: 37914862
[TBL] [Abstract][Full Text] [Related]
2. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
3. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
4. The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Shimizu T
In Vivo; 2023; 37(1):345-356. PubMed ID: 36593055
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database.
Nakao H; Koseki T; Kato K; Yamada S; Tsuboi N; Takahashi K; Mizuno T
J Pharm Pharm Sci; 2023; 26():11453. PubMed ID: 37456806
[No Abstract] [Full Text] [Related]
6. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
7. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
8. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
9. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
de Germay S; Singier A; Salvo F; Pariente A;
Drug Saf; 2023 Dec; 46(12):1381-1389. PubMed ID: 37926785
[TBL] [Abstract][Full Text] [Related]
10. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
11. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
[TBL] [Abstract][Full Text] [Related]
12. Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-series Analyses.
Hauben M; Hung E
Clin Ther; 2021 Feb; 43(2):360-368.e5. PubMed ID: 33509646
[TBL] [Abstract][Full Text] [Related]
13. Signal detection of COVID-19 vaccines adverse events using spontaneous reports from South Korea.
Jeong HS; Chun BC
Pharmacoepidemiol Drug Saf; 2023 Sep; 32(9):961-968. PubMed ID: 37019851
[TBL] [Abstract][Full Text] [Related]
14. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
Moro PL; Olson CK; Clark E; Marquez P; Strid P; Ellington S; Zhang B; Mba-Jonas A; Alimchandani M; Cragan J; Moore C
Vaccine; 2022 May; 40(24):3389-3394. PubMed ID: 35489985
[TBL] [Abstract][Full Text] [Related]
15. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
[TBL] [Abstract][Full Text] [Related]
16. Masking by vaccines in pediatric drug safety signal detection in the EudraVigilance database.
Dodd C; Pacurariu A; Osokogu OU; Weibel D; Ferrajolo C; Vo DH; Becker B; Kors JA; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1249-1256. PubMed ID: 30066460
[TBL] [Abstract][Full Text] [Related]
17. Potential Signals of COVID-19 as an Effect Modifier of Adverse Drug Reactions.
Hauben M; Hung E; Chen Y
Clin Ther; 2024 Jan; 46(1):20-29. PubMed ID: 37919188
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
19. Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports.
Riad A; Põld A; Kateeb E; Attia S
Front Public Health; 2022; 10():952781. PubMed ID: 35899169
[TBL] [Abstract][Full Text] [Related]
20. Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
Dörks M; Jobski K; Hoffmann F; Douros A
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):707-715. PubMed ID: 33650210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
